Anthony Patsy, DO
Family Medicine · Owosso, MINPI 1760652655
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $60,800 of the $68,278 with a category attached, or 89.0%. Amgen accounts for 93.1% of it on its own, with 37 other manufacturers making up the rest. Among family medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 428 payments — averaging $159.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$64K
- AbbVie$613
- Novo Nordisk$587
- Pfizer$473
- Boehringer Ingelheim$339
- Novartis$290
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$60,80089%
- Travel & lodging$8231%
- Food & beverage$6,4849%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 163 | $63,558 |
| AbbVie(2 entities) | 54 | $613 |
| Novo Nordisk | 32 | $587 |
| Pfizer | 26 | $473 |
| Boehringer Ingelheim | 14 | $339 |
| Novartis | 13 | $290 |
| Lilly USA, LLC | 15 | $265 |
| Corcept Therapeutics | 11 | $256 |
| Otsuka America Pharmaceutical, Inc. | 12 | $232 |
| AstraZeneca | 15 | $218 |
| Vanda Pharmaceuticals Inc. | 6 | $196 |
| Exact Sciences | 7 | $137 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $97 |
| Amarin Pharma, Inc. | 4 | $90 |
| Merck | 6 | $88 |
| GSK | 5 | $80 |
| Averitas Pharma Inc. | 2 | $71 |
| Collegium Pharmaceutical, Inc. | 4 | $66 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Dexcom, Inc. | 3 | $57 |
| Vertex | 2 | $53 |
| Antares Pharma, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Abbott | 2 | $40 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| BD | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Scpharmaceuticals Inc. | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Endogastric Solutions, Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,278 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 270 | $300,321 |
| OzempicSemaglutide | 194 | $261,660 |
| TrulicityDulaglutide | 107 | $179,143 |
| MounjaroTirzepatide | 110 | $125,704 |
| JanuviaSitagliptin Phosphate | 93 | $114,388 |
| Repatha SureclickEvolocumab | 135 | $110,940 |
| JardianceEmpagliflozin | 88 | $107,005 |
| Dupixent PenDupilumab | 13 | $72,632 |
| XareltoRivaroxaban | 58 | $66,290 |
| MyrbetriqMirabegron | 65 | $59,850 |
| OtezlaApremilast | 12 | $56,736 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $41,287 |
| VascepaIcosapent Ethyl | 78 | $39,457 |
| FarxigaDapagliflozin Propanediol | 39 | $39,070 |
| TradjentaLinagliptin | 27 | $28,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $265 | $304,847217 claims |
| PfizerEliquis | $473 | $300,321270 claims |
| Novo NordiskOzempic | $587 | $261,660194 claims |
| Boehringer IngelheimJardiance, Tradjenta | $339 | $135,748115 claims |
| MerckJanuvia | $88 | $114,38893 claims |
| AmgenOtezla, Evenity (2 Syringes) | $63,558 | $84,46724 claims |
| Johnson & JohnsonXarelto, Invokana | $16 | $73,28170 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $218 | $68,78993 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $59,85065 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $80 | $50,57974 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $30 | $27,62537 claims |
| Axsome Therapeutics, Inc.Auvelity | $66 | $14,59122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Owosso
- Loren ChudlerSouthfield$1.3M
- Paul BensonBerkley$779K
- Matt RosenbergJackson$550K
- Steve LasaterSaint Johns$291K
- Mary DagenGrand Rapids$265K
- Farhan BhattiLansing$230K
- Jeffrey DeitchSterling Heights$197K
- Sukhpreet SinghPlymouth$173K
- James VoigtOak Park$140K
- Timothy IzzoGrand Ledge$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.